Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CADL 
Candel Therapeutics Inc (CADL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: CADL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.62
1 Year Target Price $18.62
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 140.66% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 304.69M USD | Price to earnings Ratio - | 1Y Target Price 18.62 |
Price to earnings Ratio - | 1Y Target Price 18.62 | ||
Volume (30-day avg) 3 | Beta -0.93 | 52 Weeks Range 4.25 - 13.68 | Updated Date 01/9/2026 |
52 Weeks Range 4.25 - 13.68 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.25% | Return on Equity (TTM) -70.17% |
Valuation
Trailing PE - | Forward PE 43.48 | Enterprise Value 224929581 | Price to Sales(TTM) 436.42 |
Enterprise Value 224929581 | Price to Sales(TTM) 436.42 | ||
Enterprise Value to Revenue 821.98 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 54898303 | Shares Floating 45481597 |
Shares Outstanding 54898303 | Shares Floating 45481597 | ||
Percent Insiders 16.76 | Percent Institutions 41.82 |
Upturn AI SWOT
Candel Therapeutics Inc
Company Overview
History and Background
Candel Therapeutics Inc. was founded in 2019. It is a late-stage biotechnology company focused on developing oncolytic viral immunotherapies to treat cancer. The company emerged from the academic research of Dr. Stephen J. Russell and Dr. Kah-Wai Tam, pioneers in the field of oncolytic virotherapy. Key milestones include the progression of its lead product candidate, CAN-2404, into clinical trials.
Core Business Areas
- Oncolytic Viral Immunotherapy: Candel Therapeutics is dedicated to developing novel oncolytic viruses designed to selectively infect and kill cancer cells while stimulating the body's immune system to fight the tumor. Their approach aims to leverage the body's natural defenses for a more effective and potentially less toxic cancer treatment.
Leadership and Structure
Information on the specific leadership team and organizational structure of Candel Therapeutics Inc. would typically be found in their official investor relations materials or company filings. This typically includes a CEO, CFO, CSO, and a Board of Directors. As a biotechnology company, its structure is often geared towards research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CAN-2404: CAN-2404 is Candel Therapeutics' lead oncolytic viral immunotherapy candidate. It is designed to be administered directly into solid tumors. While specific market share data for this early-stage product is not applicable, its primary competitors are other companies developing oncolytic viruses and other forms of cancer immunotherapy. Key competitors in the broader oncolytic virus space include Amgen (with Imlygic), Replimune, and Oncolys BioPharma.
Market Dynamics
Industry Overview
The biotechnology and pharmaceutical industry, particularly the oncology sector, is characterized by intense research and development, significant investment, and a highly competitive landscape. The demand for innovative cancer treatments, including immunotherapies and oncolytic viruses, is substantial due to the high global burden of cancer. The industry is driven by scientific breakthroughs, regulatory approvals, and market access.
Positioning
Candel Therapeutics is positioned as an emerging player in the oncolytic viral immunotherapy space. Its competitive advantage lies in its proprietary oncolytic virus platform and its focus on developing novel agents with the potential to address unmet needs in various solid tumors. The company aims to differentiate itself through the potential for enhanced immune stimulation and tumor targeting.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for oncology treatments, including immunotherapies and oncolytic viruses, is in the hundreds of billions of dollars globally and continues to grow. Candel Therapeutics, with its focus on solid tumors, is targeting a significant portion of this market. The company's positioning is to capture a share of this market by offering differentiated therapeutic options for patients with limited treatment alternatives.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic viral platform.
- Focus on a promising area of cancer immunotherapy.
- Potential for novel mechanisms of action.
- Experienced scientific leadership (implied).
Weaknesses
- Early-stage development with significant clinical and regulatory risk.
- Limited historical financial data and potential for substantial R&D burn.
- Dependence on the success of a few key product candidates.
- Unproven commercial viability for their specific platform.
Opportunities
- Advancements in genetic engineering and virology.
- Growing demand for novel cancer therapies.
- Potential for combination therapies with existing treatments.
- Expansion into new tumor types and indications.
Threats
- High attrition rates in drug development.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Stringent regulatory hurdles and lengthy approval processes.
- Potential for unexpected adverse events in clinical trials.
- Funding challenges in a capital-intensive industry.
Competitors and Market Share
Key Competitors
- Replimune Group Inc. (REPL)
- Amgen Inc. (AMGN)
- Oncolys BioPharma Inc. (OCLY)
Competitive Landscape
Candel Therapeutics faces a competitive landscape with established players and emerging innovators in the oncolytic virus and broader cancer immunotherapy markets. Its advantages lie in its potentially novel therapeutic approach and targeted indications. However, it faces disadvantages in terms of resources, established market presence, and longer development timelines compared to larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: As a relatively young company, Candel Therapeutics' historical growth has been primarily in its pipeline development and clinical trial progression. Its growth has been fueled by investment and the advancement of its scientific programs.
Future Projections: Future growth projections for Candel Therapeutics Inc. are highly speculative and dependent on the successful clinical development and regulatory approval of its product candidates. Analyst estimates, if available, would focus on potential peak sales of its lead drug and expansion into various indications.
Recent Initiatives: Recent initiatives likely involve the progression of its ongoing clinical trials, potential new drug discovery efforts, strategic partnerships, and securing further funding to support its development pipeline.
Summary
Candel Therapeutics Inc. is an emerging biotechnology company with a focus on oncolytic viral immunotherapies for cancer. Its lead product, CAN-2404, shows promise, but the company operates in a high-risk, high-reward industry. Success hinges on clinical trial outcomes and regulatory approvals. Key challenges include intense competition and significant R&D expenses, while opportunities lie in unmet medical needs in oncology.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., S-1, 10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Biotechnology Industry Analysis Reports
- Company Investor Relations Websites
Disclaimers:
This JSON output is generated based on publicly available information and industry knowledge. It is intended for informational purposes only and does not constitute financial or investment advice. Market share data for early-stage companies is an estimation. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Candel Therapeutics Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2021-07-27 | President, CEO & Director Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.candeltx.com |
Full time employees 38 | Website https://www.candeltx.com | ||
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.